Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Long-term outcomes for allogeneic bone marrow transplantation in Sezary syndrome and mycosis fungoides

Bone Marrow Transplantation volume 57, pages 1724–1726 (2022)Cite this article

Subjects

Advanced-stage IIB-IV mycosis fungoides (MF) and Sezary syndrome (SS) portend a poor prognosis with median overall survival (OS) of 1.4–4.7 years and 5-year OS of 18–47% [1]. Despite the emergence of novel therapies, currently available systemic therapies are not associated with durable disease control [2] and allogeneic haematopoietic stem cell transplantation (allo-HSCT) is the only current treatment option with curative potential.

Domingo-Domenech et al. recently updated data from the European Society for Blood and Marrow Transplantation (EBMT) registry, investigating allo-HSCT outcomes in MF/SS [3]. This and preceding EBMT analyses identify a cohort of long-term survivors, response to donor lymphocyte infusion and a plateau in survival, indicating a potentially curative graft-versus-lymphoma (GVL) effect. Five-year survival and toxicity outcomes appear to show benefit, with OS of 38%, progression-free survival (PFS) of 26%, relapse rate of 45% and non-relapse mortality (NRM) of 28%.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Survival analysis in MF and SS patients following allograft. MF mycosis fungoides, SS Sezary syndrome.

Data availability

Data supporting the findings of this study are available from the corresponding author upon request.

References

  1. Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28:4730–9.

    Article  PubMed  Google Scholar 

  2. Photiou L, van der Weyden C, McCormack C, Miles Prince H. Systemic treatment options for advanced-stage mycosis fungoides and sezary syndrome. Curr Oncol Rep. 2018;20:32.

    Article  PubMed  Google Scholar 

  3. Domingo-Domenech E, Duarte RF, Boumedil A, Onida F, Gabriel I, Finel H, et al. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2021;56:1391–401.

    Article  CAS  PubMed  Google Scholar 

  4. Hosing C, Bassett R, Dabaja B, Talpur R, Alousi A, Ciurea S, et al. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol. 2015;26:2490–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Onida F, Valli V, Saporiti G, Alberti Violetti S, Grifoni F, Goldaniga M, et al. Allogeneic hematopoietic stem cell transplantation as a curative treatment strategy for patients with advanced mycosis fungoides and Sézary syndrome: 2019 update of the Milan experience [abstract]. In: 4th World Congress of Cutaneous Lymphomas; 12–14 February 2020; Barcelona Abstract number U-02.

  6. Weng WK, Arai S, Rezvani A, Johnston L, Lowsky R, Miklos D, et al. Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma. Blood Adv. 2020;4:4474–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Stolearenco V, Namini MRJ, Hasselager SS, Gluud M, Buus TB, Willerslev-Olsen A, et al. Cellular interactions and inflammation in the pathogenesis of cutaneous T-cell lymphoma. Front Cell Dev Biol. 2020;8:851.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010;116:767–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Campbell BA, Scarisbrick JJ, Kim YH, Wilcox RA, McCormack C, Prince HM. Time to next treatment as a meaningful endpoint for trials of primary cutaneous lymphoma. Cancers. 2020;12:2311.

    Article  CAS  PubMed Central  Google Scholar 

  10. Regan MM, Werner L, Rao S, Gupte-Singh K, Hodi FS, Kirkwood JM, et al. Treatment-free survival: a novel outcome measure of the effects of immune checkpoint inhibition—a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2019;37:3350–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Cetinözman F, Jansen PM, Vermeer MH, Willemze R. Differential expression of programmed death-1 (PD-1) in Sézary syndrome and mycosis fungoides. Arch Dermatol. 2012;148:1379–85.

    Article  PubMed  Google Scholar 

  12. de Masson A, Beylot-Barry M, Bouaziz JD, Peffault de Latour R, Aubin F, Garciaz S, et al. Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas. Haematologica. 2014;99:527–34.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Shiratori S, Fujimoto K, Nishimura M, Hatanaka KC, Kosugi-Kanaya M, Okada K, et al. Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome. Hematol Oncol. 2016;34:9–16.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

AK, JE, SA, HMP and DR formulated project; data collection and analysis by JE, SA, GK, JW, GH, JC, CVDW and PB. Statistical consultation was provided by senior biostatistician Michael Fahey of the Peter MacCallum Centre of Biostatistics & Clinical Trials. JE wrote the manuscript; AK, HMP, GK and DR reviewed the manuscript; all authors approved the final submission. Extensive research contribution noted with thanks and respect to the late Robert Twigger.

Author information

Authors and Affiliations

  1. Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia

    Jessica Elliott, Shalini Ahlawat, H. Miles Prince, Jenny Collins, Carrie Van Der Weyden, David Ritchie & Amit Khot

  2. Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia

    H. Miles Prince & Amit Khot

  3. Royal Brisbane and Women’s Hospital, Brisbane, QLD, Australia

    Glen Kennedy

  4. Westmead Hospital, Sydney, NSW, Australia

    Jillian Wells & Gillian Huang

  5. Royal Adelaide Hospital, Adelaide, SA, Australia

    Peter Bardy

Authors
  1. Jessica Elliott
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shalini Ahlawat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Miles Prince
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Glen Kennedy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jillian Wells
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gillian Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jenny Collins
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Peter Bardy
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Carrie Van Der Weyden
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. David Ritchie
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Amit Khot
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jessica Elliott.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Elliott, J., Ahlawat, S., Prince, H.M. et al. Long-term outcomes for allogeneic bone marrow transplantation in Sezary syndrome and mycosis fungoides. Bone Marrow Transplant 57, 1724–1726 (2022). https://doi.org/10.1038/s41409-022-01787-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-022-01787-3

This article is cited by

Search

Advanced search

Quick links